The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Midostaurin for newly diagnosed FLT3+ AML: RADIUS-X efficacy and safety data
Midostaurin was the first multikinase inhibitor approved in combination with daunorubicin and cytarabine induction, and high-dose cytarabine (HiDAC) consolidation chemotherapy, for the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, provides updated safety data for midostaurin from the Phase III RADIUS-X trial (NCT02624570). Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Perl demonstrates the continued manageable safety profile of midostaurin, with no new safety signals observed.
